science1 publisher
Lilly picked brenipatide's weekly dose from 212 volunteers enrolled by body mass index
A Phase I dose-selection study put brenipatide's half-life at 9 to 12.5 days. Lilly says that supports once-weekly dosing in the Phase III trials it is now running in major depressive disorder and alcohol use disorder.
Publishers:genengnews.com
Reality
- Evidence45
- Adoption25
- Hype gap+35
- Incentives82
- Confidence58